Bioxyne Limited (ASX:BXN)

Australia flag Australia · Delayed Price · Currency is AUD
0.0480
0.00 (0.00%)
Jul 31, 2025, 1:17 PM AEST
Market Cap103.91M
Revenue (ttm)17.33M
Net Income (ttm)2.24M
Shares Out2.16B
EPS (ttm)0.00
PE Ratio37.18
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume519,688
Average Volume5,663,716
Open0.0490
Previous Close0.0480
Day's Range0.0480 - 0.0500
52-Week Range0.0050 - 0.0530
Beta0.24
RSI66.63
Earnings DateJul 28, 2025

About Bioxyne

Bioxyne Limited, a life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, cannabis pastilles, THC flowers, vapes, oral liquids, nootropic and skin care products, and mushroom complexes. It also develops various functional food products, such as ... [Read more]

Founded 1998
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol BXN
Full Company Profile

Financial Performance

In 2024, Bioxyne's revenue was 9.64 million, an increase of 81.98% compared to the previous year's 5.30 million. Losses were -13.33 million, 586.9% more than in 2023.

Financial Statements

News

Bioxyne Delivers Australia's First Pharmaceutical Cannabis Gummies, Scales Up Manufacturing Capabilities

Australian life sciences and health products company Bioxyne Limited (ASX: BXN) announced Wednesday that its fully-owned subsidiary, Breathe Life Sciences ( BLS), has successfully manufactured and de...

1 year ago - Benzinga